A detailed history of E. Ohman J:Or Asset Management Ab transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, E. Ohman J:Or Asset Management Ab holds 4,710 shares of REGN stock, worth $4.77 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
4,710
Previous 4,510 4.43%
Holding current value
$4.77 Million
Previous $4.34 Billion 14.04%
% of portfolio
0.12%
Previous 0.11%

Shares

34 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$883.2 - $1071.19 $176,640 - $214,238
200 Added 4.43%
4,710 $4.95 Billion
Q1 2024

May 14, 2024

BUY
$902.69 - $993.35 $279,833 - $307,938
310 Added 7.38%
4,510 $4.34 Billion
Q4 2023

Feb 15, 2024

BUY
$775.18 - $881.7 $3.26 Million - $3.7 Million
4,200 New
4,200 $3.69 Billion
Q2 2023

Apr 05, 2024

BUY
$700.03 - $830.35 $490,021 - $581,245
700 Added 8.11%
9,329 $6.7 Billion
Q1 2023

Apr 05, 2024

BUY
$680.49 - $826.97 $612,441 - $744,273
900 Added 11.64%
8,629 $7.09 Billion
Q4 2022

Apr 05, 2024

SELL
$705.89 - $766.39 $3.49 Million - $3.79 Million
-4,950 Reduced 39.04%
7,729 $5.58 Billion
Q3 2022

Apr 05, 2024

SELL
$573.97 - $724.32 $2.41 Million - $3.05 Million
-4,204 Reduced 24.9%
12,679 $8.73 Billion
Q2 2022

Apr 05, 2024

SELL
$548.35 - $738.84 $1.15 Million - $1.55 Million
-2,100 Reduced 11.06%
16,883 $9.98 Billion
Q1 2022

Apr 05, 2024

BUY
$595.12 - $698.43 $8.26 Million - $9.7 Million
13,883 Added 272.22%
18,983 $13.3 Billion
Q4 2021

Apr 05, 2024

BUY
$543.48 - $670.97 $217,392 - $268,388
400 Added 8.51%
5,100 $3.22 Billion
Q3 2021

Apr 05, 2024

BUY
$574.03 - $680.96 $114,806 - $136,192
200 Added 4.44%
4,700 $2.84 Billion
Q2 2021

Apr 05, 2024

BUY
$472.8 - $558.54 $189,120 - $223,416
400 Added 9.76%
4,500 $2.51 Billion
Q1 2021

Apr 05, 2024

SELL
$446.73 - $548.2 $44,673 - $54,820
-100 Reduced 2.38%
4,100 $1.94 Billion
Q3 2020

Apr 05, 2024

BUY
$544.75 - $658.21 $217,900 - $263,284
400 Added 10.53%
4,200 $2.35 Billion
Q2 2020

Apr 05, 2024

BUY
$493.32 - $643.92 $394,656 - $515,135
800 Added 26.67%
3,800 $2.37 Billion
Q1 2020

Apr 05, 2024

SELL
$336.18 - $494.43 $268,944 - $395,544
-800 Reduced 21.05%
3,000 $1.46 Billion
Q4 2019

Apr 05, 2024

BUY
$274.13 - $376.51 $82,239 - $112,953
300 Added 8.57%
3,800 $1.43 Billion
Q3 2019

Apr 05, 2024

SELL
$273.46 - $318.39 $11.4 Million - $13.3 Million
-41,674 Reduced 92.25%
3,500 $971 Million
Q2 2019

Apr 05, 2024

SELL
$299.6 - $414.82 $1.38 Million - $1.9 Million
-4,590 Reduced 9.22%
45,174 $14.1 Billion
Q1 2019

Apr 05, 2024

BUY
$372.08 - $439.57 $2.89 Million - $3.41 Million
7,759 Added 18.47%
49,764 $20.4 Billion
Q4 2018

Apr 05, 2024

BUY
$335.82 - $403.04 $5.81 Million - $6.97 Million
17,287 Added 69.94%
42,005 $15.7 Billion
Q3 2018

Apr 05, 2024

BUY
$351.14 - $408.51 $609,930 - $709,581
1,737 Added 7.56%
24,718 $9.99 Billion
Q2 2018

Apr 05, 2024

BUY
$284.6 - $344.99 $5.91 Million - $7.17 Million
20,781 Added 944.59%
22,981 $7.93 Billion
Q1 2018

Apr 05, 2024

SELL
$315.82 - $393.78 $94,746 - $118,133
-300 Reduced 12.0%
2,200 $758 Million
Q4 2017

Apr 05, 2024

BUY
$358.63 - $469.95 $143,452 - $187,980
400 Added 19.05%
2,500 $940 Million
Q1 2017

Apr 05, 2024

BUY
N/A
400 Added 23.53%
2,100 $814 Million
Q3 2016

Apr 05, 2024

BUY
N/A
200 Added 13.33%
1,700 $683 Million
Q4 2015

Apr 05, 2024

BUY
N/A
200 Added 15.38%
1,500 $814 Million
Q3 2015

Apr 05, 2024

SELL
N/A
-300 Reduced 18.75%
1,300 $605 Million
Q2 2014

Apr 05, 2024

SELL
N/A
-400 Reduced 20.0%
1,600 $452 Million
Q3 2013

Apr 05, 2024

BUY
N/A
400 Added 25.0%
2,000 $626 Million
Q2 2013

Apr 05, 2024

SELL
N/A
-500 Reduced 23.81%
1,600 $360 Million
Q4 2012

Apr 05, 2024

BUY
N/A
600 Added 40.0%
2,100 $359 Million
Q2 2012

Apr 05, 2024

SELL
N/A
-2,700
1,500 $171 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $109B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track E. Ohman J:Or Asset Management Ab Portfolio

Follow E. Ohman J:Or Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.